Add like
Add dislike
Add to saved papers

Phase I Designs that Allow for Uncertainty in the Attribution of Adverse Events.

In determining dose limiting toxicities in Phase I studies, it is necessary to attribute adverse events (AE) to being drug related or not. Such determination is subjective and may introduce bias. In this paper, we develop methods for removing or at least diminishing the impact of this bias on the estimation of the maximum tolerated dose (MTD). The approach we suggest takes into account the subjectivity in the attribution of AE by using model-based dose escalation designs. The results show that gains can be achieved in terms of accuracy by recovering information lost to biases. These biases are a result of ignoring the errors in toxicity attribution.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app